414910-03-5

Basic information

• Product Name: 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphen yl)-N-methyl-4-oxo-, (2R)-
• Synonyms: 2-(R)-(4-fluoro-2-methyl-phenyl)-4-oxo-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)ethyl]-methylamide;2-(R)-(4-fluoro-2-methylphenyl)-4-oxopiperidine-1-carboxylic acid [1-((R)-3,5-bis-trifluoromethylphenyl)ethyl]methylamide;(2R)-1-[N-{1-(R)-(3,5-bistrifluoromethylphenyl)ethyl}-N-methylamino-carbonyl]-2-(4-fluoro-2-methylphenyl)-4-oxopiperidine;2-(R)-(4-fluoro-2-methyl-phenyl)-4-oxo-piperidine-1-carboxylic acid [1-(R)-3,5-bis-(trifluoromethyl-phenyl)-ethyl]-methylamide;(2R)-1-{N-(1-(R)-3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4- fluoro-2-methylphenyl)-4-oxopiperidine
• CAS NO: 414910-03-5
• Molecular Formula: C24H23F7N2O2
• Molecular Weight: 504.448
• Mol File: 414910-03-5.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphen yl)-N-methyl-4-oxo-, (2R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphen yl)-N-methyl-4-oxo-, (2R)-(414910-03-5)
• EPA Substance Registry System: 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphen yl)-N-methyl-4-oxo-, (2R)-(414910-03-5)

Safety Data

• Hazardous Substances Data: 414910-03-5(Hazardous Substances Data)

Upstream product

• 629953-69-1 2-(4-fluoro-2-methylphenyl)-4,4-dimethoxypiperidine 
• 334477-60-0 [(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl](methyl)amine 
• 414909-99-2 2-(4-fluoro-2-methyl-phenyl)-piperidine-4-one 
• 414910-05-7 (1R)-1-[3,5-bis(trifluoromethyl)phenyl]-N-methylethanaminehydrochloride 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 414910-12-6 (2R)-2-(4-fluoro-2-methylphenyl)-4-piperidinone 
• 17199-29-0 (S)-Mandelic acid 
• 452-63-1 2-Bromo-5-fluorotoluene 
• 579475-69-7 2-(4-fluoro-2-methylphenyl)-4-piperidinone camphor-10-sulfonate 
• 414910-13-7 (2R)-2-(4-fluoro-2-methylphenyl)-4-piperidinone L-(+)-mandelate 
• 414910-00-2 2-(4-fluoro-2-methyl-phenyl)-4-oxo-piperidine-1-carboxylic acid benzyl ester 
• 414909-98-1 phenylmethyl 2-(4-fluoro-2-methylphenyl)-4-oxo-3,4-dihydro-1(2H)-pyridinecarboxylate 
• 620-08-6 4-methoxypyridine 

Downstream Products

• 414910-27-3 [14C]-Casopitant 
• 414910-41-1 2-(R)-(4-fluoro-2-methyl-phenyl)-4-(R)-[(4-tert-butoxycarbonyl)-piperazin-1-yl]-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide 
• 414910-42-2 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-[(4-tert-butoxycarbonyl)-piperazin-1-yl]-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide 
• 921206-86-2 GSK₆₃₁₈₃₂ 
• 579475-18-6 Orvepitant 
• 1265855-31-9 C₂₇H₃₀F₇N₃O 
• 1265855-27-3 C₂₇H₃₀F₇N₃O 
• 758683-83-9 C₂₈H₃₂F₇N₃O 
• 732982-99-9 C₂₈H₃₂F₇N₃O 
• 578711-32-7 C₂₈H₃₂F₇N₃O 
• 578711-34-9 C₂₈H₃₂F₇N₃O 
• 578710-96-0 C₂₆H₃₀F₇N₃O 
• 578710-94-8 C₂₆H₃₀F₇N₃O 
• 578711-16-7 C₂₅H₂₈F₇N₃O 

Relevant articles and documents

Application of the QbD principles in the development of the casopitant mesylate manufacturing process. Process research studies for the definition of the control strategy of some drug substance-CQAs for stages 2a, 2b, and 2c

Casopitant was identified as a potent NK1 antagonist by GlaxoSmithKline (GSK). It was selected as part of a wide drug discovery programme within GSK for its potential activities on a number of therapeutic targets such as inflammatory bowel dise

ANHYDROUS CRYSTAL FORM OF ORVEPITANT MALEATE

The invention relates to anhydrous crystalline orvepitant maleate (Form 1), pharmaceutical formulations comprising the same, its use in therapy and processes for preparing the same.

Chemical compounds

Formula (1) wherein R represents a halogen atom or a C1-4 alkyl group; R1 represents a C1-4 alkyl group; R2 represents hydrogen or a C1-4 alkyl group; R3 represents hydrogen, or a C1-4 alkyl group; R4 represents a trifluorometyl group; R5 represents hydrogen, a C1-4 alkyl group or C(0)R6; R6? represents C1-4 alkyl, C3-7 cycloalkyl, NH(C1-4 alkyl) or N(C1-4alkyl)2; m is zero or an integer from 1 to 3; n is an integer from 1 to 3 and pharmaceutically acceptable salts and solvates thereof; to processes for their preparation and their use in the treatment of conditions mediated bytachykinins.